Sanofi India Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ended December 31, 2025, with stock exchanges BSE Limited and the National Stock Exchange of India Limited. The report, submitted on April 2, 2026, forms part of the company's Integrated Annual Report and demonstrates its commitment to environmental, social, and governance (ESG) principles.

Financial and Operational Overview

The pharmaceutical company reported strong financial metrics for FY25, with key parameters highlighting its market position and operational scale.

The company operates with a workforce of 1,104 employees and workers across its operations, including 871 permanent employees and 226 permanent workers. The organization maintains facilities in Mumbai and Goa, with manufacturing operations focused on drugs and pharmaceuticals contributing 100% of turnover.

Environmental Performance and Climate Action

Sanofi India has achieved significant progress in its environmental commitments, particularly in greenhouse gas emissions reduction and renewable energy adoption. The company has established ambitious targets aligned with global climate goals.

The company has implemented several environmental initiatives including zero liquid discharge systems, effluent treatment plants, and HFO-based chillers expected to reduce carbon footprint by approximately 1,500 tons annually. Water stewardship plans have been implemented across sites, with treated wastewater being repurposed for gardening and other non-potable uses.

Employee Welfare and Human Resources

The sustainability report highlights comprehensive employee welfare measures and diversity initiatives across the organization.

Workforce Demographics and Benefits

The company provides comprehensive benefits including health insurance, accident coverage, maternity and paternity benefits, and day care facilities. Training programs covered 100% of board members, key management personnel, and employees, focusing on areas such as ethics, safety, human rights, and professional development.

Corporate Social Responsibility Impact

Sanofi India's CSR initiatives have created substantial community impact, particularly in healthcare access and diabetes awareness programs.

The programs target vulnerable and marginalized communities, with 100% of beneficiaries from these groups across health-focused initiatives. The company's approach emphasizes preventive healthcare, health education, and improving access to quality medical services in underserved areas.

Governance and Compliance Framework

The report demonstrates robust governance structures with dedicated oversight mechanisms for ESG matters. The Managing Director chairs a management-level ESG committee comprising senior leaders from various functions including finance, HR, safety, and communications.

Key governance highlights include updated Code of Conduct aligned with Indian laws and global standards, comprehensive anti-bribery policies, and mechanisms for conflict of interest management. The company maintains zero tolerance for corruption and has implemented whistleblower protection measures.

Stakeholder Engagement and Value Chain

Sanofi India engages with diverse stakeholder groups including patients, healthcare professionals, employees, suppliers, and local communities through structured communication channels. The company assessed 1,611 suppliers for sustainability performance in 2025, with 92% meeting sustainability requirements across areas including health and safety practices, working conditions, and human rights standards.

The sustainability report reflects Sanofi India's integrated approach to business responsibility, combining operational excellence with environmental stewardship and social impact. The comprehensive disclosure demonstrates the company's commitment to transparency and accountability in its ESG journey while supporting India's sustainable development objectives.

Sanofi India Limited has received Central Government approval for the appointment of Mr. Deepak Arora as Managing Director, marking a significant milestone in the company's leadership transition. The pharmaceutical company informed the stock exchanges about this development on April 2, 2026.

Government Approval Details

The Ministry of Corporate Affairs granted approval for Mr. Deepak Arora's appointment through its letter dated April 1, 2026. The approval covers his tenure as Managing Director for a three-year period under the Companies Act, 2013.

Previous Intimations and Timeline

Sanofi India had previously informed the exchanges about Mr. Arora's appointment on two occasions - October 27, 2025 and December 18, 2025 - with the caveat that it was subject to Central Government approval. The company filed its application with the government on January 21, 2026, through SRN AC1430577.

Regulatory Conditions

The government approval comes with specific conditions that Mr. Arora must adhere to during his tenure:

• He must provide an undertaking that he will not become interested in any selling agency of the company without prior government approval
• This restriction extends to his wife and minor children
• His headquarters shall be fixed at the place where he regularly stays for attending duties
• The appointment remains conditional upon furnishing the required undertaking

Compliance and Notifications

Company Secretary and Compliance Officer Haresh Vala signed the notification to the exchanges, ensuring compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The approval letter was received via email on April 1, 2026, and promptly communicated to BSE and NSE the following day.

The government clarified that this approval is specific to the Companies Act, 2013 provisions and does not cover requirements under other laws or regulations. The appointment will be governed by relevant provisions of the Act regarding management powers and related matters.